Key content: The prevalence of preterm birth is increasing and owing to advances in
neonatal care, more infants are surviving. However, in parallel with this, the incidence of …

Cerebral palsy occurs in three to four infants per 1000 live births. Preterm birth prior to 34
weeks' gestation is a major risk factor. Five randomized controlled trials of antenatal …

Introduction The risk for brain injury manifested as cerebral palsy is higher in very preterm
born children than in term. Prenatal administration of magnesium sulfate (MgSO4) has been …

ABSTRACT Background: Magnesium sulfate (MgSO4) can be used for the primary
prevention of cerebral palsy in preterm infants less than 37 weeks of gestational age. Aim …

Background Intravenous administration of magnesium sulfate (MgSO4) to expectant
individuals before childbirth, has been evaluated to reduce the likelihood of mortality and …

Antenatal magnesium sulphate reduces the risk of cerebral palsy in babies born< 30 weeks'
gestation. A guideline for its use in women at imminent risk of preterm birth was …

The administration of magnesium sulphate to mothers at risk for preterm birth for fetal
neuroprotection has demonstrated to reduce the risk of cerebral palsy and gross motor …

Prevention of neurologic disability associated with preterm birth is one of the major
challenges in current perinatal medicine. Magnesium sulfate (MgSO4), the focus of this …

Background Survival of preterm infants has improved drastically. In addition to significant
contribution to neonatal mortality, impact of prematurity among survivors may continue …

Objective The objective is to provide guidelines for the use of antenatal magnesium sulphate
for fetal neuroprotection of the preterm infant. Options Antenatal magnesium sulphate …